Joe Biden-Kamala Harris Administration on High Alert as Mpox Threat Looms Outside Africa

The Biden-Harris administration has acknowledged growing concerns over the spread of mpox, a highly infectious disease that has resurfaced outside of Africa, sparking fears of a global health threat. As cases rise, particularly in the Democratic Republic of the Congo (DRC), the U.S. government has ramped up its response, establishing an "incident response structure" across federal agencies to bolster domestic preparedness.

Mpox, formerly known as monkeypox, has drawn increased attention after the World Health Organization (WHO) reinstated the clade I strain of the virus as a Public Health Emergency of International Concern on August 21. The virus, which had previously been confined to Africa, has now made its way to Europe, with Sweden confirming its first case on August 22. This development has prompted international health agencies to raise the alarm, emphasizing the need for heightened vigilance.

Dr. Pamela Rendi-Wagner, director of the European Centre for Disease Prevention and Control, has underscored the importance of preparedness due to the close links between Europe and Africa. Although the Centers for Disease Control and Prevention (CDC) has not reported any cases of clade I mpox in the United States, officials warn that the spread of the virus from Africa must be closely monitored.

While the Biden administration remains on high alert, experts are cautious about jumping to conclusions regarding the severity of the virus. UCLA epidemiologist Anne Rimoin emphasized that while clade I mpox is considered more severe than its clade II counterpart, the data on its true impact is still limited. Rimoin noted that the perceived severity might be influenced by various factors, including the population it affects, their immune systems, and the route of transmission.

The concern stems from clade I mpox's higher transmissibility and severity compared to clade II, which led to a global outbreak in 2022. Immunocompromised individuals, particularly those with untreated HIV, are believed to be at greater risk of severe illness, hospitalization, and death if infected with clade I.

In light of these concerns, Harvard Medical School virologist Dr. Dan Barouch has warned that the U.S. could see cases of clade I mpox in the near future, though he reassures that the current risk remains low. However, Barouch emphasized the importance of maintaining vigilance to prevent the virus from gaining a foothold.

The CDC first issued warnings about potential clade I cases in December and updated its advisory earlier this month. The agency is closely monitoring the situation, particularly after a recent study in the DRC showed promising results from the TPOXX antiviral treatment. Although the vaccine did not significantly reduce symptoms of clade I mpox, it did lower the mortality rate to 1.7 percent, compared to the typical death rate of 3.6 percent or higher in the region.

Dr. Jennifer McQuiston, who leads the CDC's mpox clade I response, expressed cautious optimism about the study's findings, especially for patients in countries with higher-quality healthcare systems like the U.S. However, McQuiston reiterated the need for early detection and global monitoring to stay ahead of the virus's spread.

As the Biden-Harris administration continues to monitor the situation closely, the public is urged to remain informed and vigilant as global health authorities work to contain this emerging threat.